Skip to main content
Premium Trial:

Request an Annual Quote

Lawrence Berkeley Lab, Cleveland Clinic Negotiate Licensing Deals

Licensing institution: Lawrence Berkeley National Lab and the US Department of Energy Joint Genome Institute/University of California
Primary inventors: David Humphries and Martin Pollard, staff engineers, LBL and JGI
Licensee: Bio-Rad Laboratories, Hercules, Calif.
Relevant patents: US No. 7,148,778 and US No. 6,954,128, both entitled “High performance hybrid magnetic structure for biotechnology applications.”
Technology: Bio-Rad has licensed a protein and DNA separation technology to be used in life sciences research, food safety testing, and human clinical diagnostics, according to LBL. The technology is a hybrid of permanent magnet and ferromagnetic materials, producing magnetic fields 70 percent higher than the best commercial magnet plates on the market, LBL said.

Licensing institution: Cleveland Clinic
Primary inventor: Anthony Calabro, project staff, biomedical engineering, Cleveland Clinic
Licensee: Lifecore Biomedical
Relevant patent: US No. 6,982,298, “Hydroxyphenyl cross-linked macromolecular network and applications thereof.”
Technology: Lifecore has licensed a Cleveland Clinic-owned hyaluronan-based cross-linking technology that can be used for products in aesthetics, orthopedics, ophthalmology, and other medical fields. Specifically, the technology is a dihydroxyphenyl cross-linked macromolecular network that is useful in artificial tissue and tissue engineering applications, such as artificial or synthetic cartilage.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.